These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3554158)

  • 1. Molsidomine: alternative approaches to treat myocardial ischemia.
    Nitz RE; Fiedler VB
    Pharmacotherapy; 1987; 7(1):28-37. PubMed ID: 3554158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological basis of therapy with molsidomine].
    Bassenge E
    Herz; 1982 Oct; 7(5):296-306. PubMed ID: 6897544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of occlusive coronary artery thrombosis and myocardial ischemia by molsidomine in anesthetized dogs.
    Fiedler VB
    Can J Physiol Pharmacol; 1982 Aug; 60(8):1104-11. PubMed ID: 6897011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Redistribution of the coronary blood flow, functional improvement of the ischemic myocardium and reduction of the size of an experimental infarction by molsidomine].
    Berdeaux A; Giudicelli JF
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):511-5. PubMed ID: 6364947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-ischemic actions of molsidomine by venous and large coronary dilatation in combination with antiplatelet effects.
    Bassenge E; Mülsch A
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S23-8. PubMed ID: 2484695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.
    Żorniak M; Mitręga KA; Porc M; Krzemiński TF
    Can J Physiol Pharmacol; 2017 Feb; 95(2):111-121. PubMed ID: 27918857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molsidomine.
    Reden J
    Blood Vessels; 1990; 27(2-5):282-94. PubMed ID: 2242448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of coronary blood flow during exercise.
    Duncker DJ; Bache RJ
    Physiol Rev; 2008 Jul; 88(3):1009-86. PubMed ID: 18626066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dihydroergotamine on hemodynamic molsidomine actions in anesthetized dogs.
    Fiedler VB; Göbel H; Nitz RE
    Can J Physiol Pharmacol; 1984 Jun; 62(6):634-9. PubMed ID: 6547632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molsidomine in the treatment of coronary insufficiency].
    Weber S
    Rev Med Interne; 1987; 8(4):437-43. PubMed ID: 2892240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of molsidomine on platelet activation in coronary ischemia].
    Wautier JL
    Presse Med; 1988 May; 17(20):1037-40. PubMed ID: 2969100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
    Bult H; Fret HR; Herman AG
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S120-3. PubMed ID: 2484689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial actions of nitrates in cardiovascular disease.
    Abrams J
    Am J Cardiol; 1996 May; 77(13):31C-7C. PubMed ID: 8638524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro--inhibition of 12-HPETE biosynthesis.
    Darius H; Ahland B; Rücker W; Klaus W; Peskar BA; Schrör K
    J Cardiovasc Pharmacol; 1984; 6(1):115-21. PubMed ID: 6199592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-ischemic effects of SIN-1, a molsidomine metabolite, during coronary angioplasty and antiplatelet effects in humans].
    Darius H; Erbel E; Schmucker B; Reusch U; Meyer J
    Presse Med; 1988 May; 17(20):1033-6. PubMed ID: 2969099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracoronary linsidomine abolishes acetylcholine-induced vasoconstriction of epicardial coronary arteries.
    Dubois-Rande JL; Dupouy P; Geschwind H; Castaigne A; Adnot S
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):462-7. PubMed ID: 7504139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential interactions between iloprost and SIN-1 on platelet aggregation and myocardial infarct size in vivo.
    Aitchison KA; Coker SJ
    Eur J Pharmacol; 1999 Jun; 374(1):59-69. PubMed ID: 10422641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIN-1 has no direct myocardial anti-ischemic action.
    Kober G; Bender M; Vallbracht C; Sievert H; Klepzig H
    Clin Cardiol; 1993 Oct; 16(10):717-22. PubMed ID: 8222384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity of molsidomine in experimental models of ischemic cardiac disease.
    Nitz RE; Martorana PA
    Am Heart J; 1985 Mar; 109(3 Pt 2):631-6. PubMed ID: 3919549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of molsidomine, nitroglycerin and isosorbide dinitrate on experimentally induced coronary artery thrombosis in the dog.
    Martorana PA; Kettenbach B; Göbel H; Nitz RE
    Basic Res Cardiol; 1984; 79(5):503-12. PubMed ID: 6439183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.